On October 28, NeuroXess made an announcement regarding the successful completion of its Series B funding round, amassing RMB 700 million. This round was co-led by SDIC Juli Capital, Shenzhen Capital Group, and Qianzhi Capital, with significant contributions from a diverse array of institutions including SMIC Poly Capital, Huangpu Investment, Cornerstone Capital, and IDG Capital. Notably, existing shareholders such as Shanda and Zhongping Capital also continued their support. The fresh capital injection will be earmarked for advancing multi-center clinical trials and securing registration approval for NeuroXess’s groundbreaking “three fulls” brain-computer interface (BCI) system—a fully implantable, fully wireless, and fully functional innovation. Additionally, the funds will facilitate the establishment of mass production capabilities at a state-of-the-art facility, drive the development of next-generation products, and fuel exploration into the seamless integration of BCI and AI technologies. NeuroXess has already successfully conducted 65 clinical trials and is now poised to accelerate the large-scale commercialization of its products in the medical market within the next two years.